News
TFFP
6.04
-8.35%
-0.55
TFF Pharmaceuticals GAAP EPS of -$2.01, revenue of $0.1M
TFF Pharmaceuticals, Inc. Reports Q4 GAAP EPS of -$2.01, revenue of $0.1M. As of December 31, 2023, the company's cash and cash equivalents were approximately $5.5 million. The company is expected to report Q4 results on March 28, 2024.
Seeking Alpha · 3h ago
TFF Pharmaceuticals Q4 EPS $(2.01) Beats $(2.12) Estimate, Sales $114.33K Beat $100.00K Estimate
TFF Pharmaceuticals reported quarterly losses of $2.01 per share. The company reported quarterly sales of $114.33 thousand which beat the analyst consensus estimate by 14.33%. The company also beat the sales for the same period last year of $312.78 thousand.
Benzinga · 3h ago
*TFF Pharmaceuticals 4Q Rev $114,328 >TFFP
Dow Jones · 3h ago
*TFF Pharmaceuticals 4Q R&D Expenses $3M >TFFP
Dow Jones · 3h ago
Press Release: TFF Pharmaceuticals Reports Fourth -2-
Development of a drug product incorporating the TFF platform. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. The Company's annual report on Form 10-K filed with the SEC on March 28, 2024 includes the risk that the Company may not be able to obtain additional working capital.
Dow Jones · 4h ago
*TFF Pharmaceuticals 4Q Loss/Shr $2.01 >TFFP
Dow Jones · 4h ago
TFF Pharmaceuticals Is Maintained at Buy by Roth MKM
Dow Jones · 7h ago
TFF Pharmaceuticals Price Target Cut to $44.00/Share From $56.00 by Roth MKM
Dow Jones · 7h ago
Roth MKM Maintains Buy on TFF Pharmaceuticals, Lowers Price Target to $44
Benzinga · 7h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 1d ago
TFF Pharmaceuticals Shares Key Updates with Investors
TipRanks · 1d ago
TFF Pharmaceuticals Announces Oral Presentation Of Interim Data From The Phase 2 Study Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection At The 44th Annual ISHLT 2024 Meeting
TFF Pharmaceuticals, Inc. Accepted late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and Lung Transplantation meeting in April 2024. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its Thin Film Freezing (TFF) technology.
Benzinga · 3d ago
Weekly Report: what happened at TFFP last week (0318-0322)?
Weekly Report · 3d ago
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation
TFF Pharmaceuticals, Inc. Will present its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and Lung Transplantation meeting in April 2024. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products.
Barchart · 3d ago
TFF Pharmaceuticals announces $1.2M registered direct offering
TFF Pharmaceuticals, Inc. Announces $1.2M registered direct offering. The company expects to use proceeds from the offering for working capital and general corporate purposes. The offering is expected to close in March 2024, the company says. TFF pharmaceuticals is a biopharmaceutical company.
Seeking Alpha · 03/20 16:46
TFF Pharma gains after portfolio shakeup
TFF Pharmaceuticals, Inc. (TFFP) traded higher after announcing decision to prioritize its TFF TAC program targeted at lung transplants. Fort Worth, Texas-based biopharma’s lead programs include TFF VORI studies to prevent acute rejection in lung transplanted patients.
Seeking Alpha · 03/20 14:41
JAGX and GNPX among Health Care movers
On the Move JAGX and GNPX among Health Care movers. S&P 500 Health Care Sector -0.52% to 1692.4. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is down 0.67%. SCWorx Corp, XTLB, WORX, TFFP, TSHA, FEMY among health care sector gainers.
Seeking Alpha · 03/20 14:13
TFF Pharmaceuticals Announces Clinical Programs Update And Strategic Prioritization; Company To Prioritize TFF TAC Program Based On Phase 2 Data
Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) in Lung Transplant Medicine. Company to hold a conference call on March 27, 2024 to discuss clinical updates on TFF Tac and TFF VORI.
Benzinga · 03/20 13:10
TFF Pharmaceuticals Announces Update on Clinical Programs
Barchart · 03/20 08:03
Weekly Report: what happened at TFFP last week (0311-0315)?
Weekly Report · 03/18 09:52
More
Webull provides a variety of real-time TFFP stock news. You can receive the latest news about Tff Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TFFP
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF), technology platform. The TFF platform is designed to improve the solubility of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The Company has two product candidates in clinical trials, which include TFF Voriconazole Inhalation Powder (TFF VORI) and TFF Tacrolimus Inhalation Powder (TFF TAC). TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF TAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine.